CollPlant Biotechnologies (CLGN) Q3 2025 earnings summary

Executive summary

• Expanded North American sales of rhCollagen and Biolnk through a new U.S.-based logistics center and new commercial leadership, aiming to strengthen distribution and customer support in the region.

• Achieved a $2 million milestone payment from AbbVie for progress in dermal and soft tissue filler development; lead candidate is in clinical phase with ongoing data review.

• Announced cost reduction and workforce reduction plan, prioritizing key programs and extending cash runway.

• Leadership transition with CEO Yehiel Tal nominated as interim Chairman, following the outgoing Board Chairman.

Financial highlights

• Q3 2025 GAAP revenues were $77,000, up from $4,000 in Q3 2024, mainly due to increased rhCollagen-based product sales.

• Nine-month 2025 GAAP revenues reached $2.3 million, up from $351,000 year-over-year, driven by a $2 million AbbVie milestone payment.

• Q3 2025 GAAP net loss was $3.5 million ($0.27/share), improved from $4.3 million ($0.38/share) in Q3 2024; nine-month net loss was $8.3 million ($0.69/share), improved from $12.7 million ($1.11/share) year-over-year.

• Non-GAAP net loss for Q3 2025 was $3.2 million ($0.25/share), and $7.0 million ($0.58/share) for the nine months, both improved year-over-year.

• Cash and cash equivalents as of September 30, 2025, were $8.5 million.

Outlook and guidance

• Focus in 2026 will be on advancing the AbbVie collaboration and the company’s own dermal filler candidate.

• Plans to seek a strategic partner for the regenerative breast implant program.

• Cost reduction and program prioritization expected to extend cash runway.